We also found that CXCR3+ ABCs (CD19+CD21loCD11c+) coexpressing the immune checkpoint ligands PD-L1 and PD-L2 were significantly enriched in people with eMS versus healthy controls (Wilcoxon P = 0.031; Figure 5F). The gene discussed is CD19; the disease is eosinophilia-myalgia syndrome.